Page 2 - Jamie Lacey Moreira News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jamie lacey moreira. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jamie Lacey Moreira Today - Breaking & Trending Today

MaxCyte Inc. (via Public) / License with Sana Biotechnology

MaxCyte Inc. (via Public) / License with Sana Biotechnology
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , David Deuchler , Jamie Lacey Moreira , Nick Adams , Doug Doerfler , Duncan Monteith Matthew Odowd , Amanda Murphy , Chris Welsh , Mary Jane Elliott , Emma Earl Freddy Crossley , Panmure Gordon , Rupert Dearden , Maxcyte Inc , Stifel Nicolaus Europe , Gilmartin Group , Sana Biotechnology Inc , Numis Securities , Consilium Strategic Communications , Maxcyte Signs Clinical , Commercial License , Flow Electroporation , Sana Biotechnology , Cyte Contacts , Chief Executive , Chief Financial ,

MaxCyte Signs Clinical and Commercial License with Sana Biotechnology

MaxCyte Signs Clinical and Commercial License with Sana Biotechnology
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Duncan Monteith Matthew , David Deuchler , Jamie Lacey Moreira , Nick Adams , Doug Doerfler , Amanda Murphy , Chris Welsh , Mary Jane Elliott , Emma Earl Freddy Crossley , Panmure Gordon , Rupert Dearden , Maxcyte Inc , Prnewswire Maxcyte Inc , Sana Biotechnology Inc , Stifel Nicolaus Europe , Gilmartin Group , Consilium Strategic Communications , Numis Securities , Sana Biotechnology , Flow Electroporation , Cyte Contacts , Chief Executive Officer , Chief Financial , Joint Corporate Broker ,

GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancr

Search jobs
10-Apr-2021
GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model
Study demonstrates GMI-1757’s impact on immune cell infiltration and improvement of anti-PD-L1 therapeutic activity
ROCKVILLE, Md. (BUSINESS WIRE) GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a new glycomimetic with dual antagonism to E-selectin and galectin-3, has been accepted for a poster presentation at the American Association of Cancer Research (AACR) 2021 Annual Meeting, to be held virtually on April 10-15 and May 17-21. ....

United States , Jamie Lacey Moreira , Shari Annes , John Magnani , Williame Fogler , Exchange Commission , Glycomimetics Inc , American Association Of Cancer Research , American Association , Cancer Research , Mimetics Senior Vice President , Chief Scientific Officer John Magnani , Company Sponsored Phase , Biohealth Capital , ஒன்றுபட்டது மாநிலங்களில் , ஜேமி லேசி மோர்ர , ஷரி அன்ஸ் , ஜான் மஞ்ானி , பரிமாற்றம் தரகு , அமெரிக்கன் சங்கம் ஆஃப் புற்றுநோய் ஆராய்ச்சி , அமெரிக்கன் சங்கம் , புற்றுநோய் ஆராய்ச்சி , நிறுவனம் ஆதரவளிக்கப்பட்ட கட்டம் ,

Positive Findings From Phase 1b Trial of GlycoMimetics' GMI-1359 To Be Presented at AACR 2021 Meeting

Press release content from Business Wire. The AP news staff was not involved in its creation.
Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting
April 10, 2021 GMT
ROCKVILLE, Md. (BUSINESS WIRE) Apr 10, 2021
GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that a Phase 1b trial of GMI-1359, being conducted at Duke University Cancer Center, showed evidence of on-target effects, immune-activation and cell mobilization in the initial two patients treated with the Company’s dual antagonist of E-selectin and CXCR4. Dorothy Sipkins, MD, PhD, Associate Research Professor in Pharmacology and Cancer Biology at Duke University School of Medicine, will present results from the proof-of-concept clinical study as well as a separate preclinical study supporting the positive biologic findings of the Phase 1b study. The presentation will be made at the American Association of Cancer Research (AACR) 2021 Annual Meeting, whic ....

United States , Dorothy Sipkins , Jamie Lacey Moreira , Ericj Feldman , Shari Annes , Exchange Commission , Duke University Cancer Center , Glycomimetics Inc , American Association Of Cancer Research , Research Professor In Pharmacology , Associate Research Professor , Cancer Biology , Duke University School , American Association , Cancer Research , Glycomimetics Senior Vice President , Chief Medical Officer , Orphan Drug , Rare Pediatric Disease , Company Sponsored Phase , Biohealth Capital , Investor Contact , Business Wire , ஒன்றுபட்டது மாநிலங்களில் , ஜேமி லேசி மோர்ர , ஷரி அன்ஸ் ,

APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia

APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
Foster City, CA, Hangzhou, CH, Gaithersburg, MD, Jan 07, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics (Nasdaq: GLYC), today announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML).
This Breakthrough Therapy Designation for APL-106 reinforces its potential and is an important regulatory milestone for Apollomics as we prepare to initiate our clinical development work in China for patients suffering from AML, said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. AML is an aggressive disease and relapsed ....

Hong Kong , Remy Bernarda , Jamie Lacey Moreira , Shari Annes , Guo Liang Yu , Yang Xiaofeng , Zhang Sufen , Zhang Qingyuan , Kelly Fung , Wilsonw Cheung , Porda Havas International Finance Communications Group , Asia Corporate News Network , Drug Administration , Exchange Commission , National Cancer Institute Surveillance , China National Medical Products Administration , Glycomimetics Inc , Corporate Communications , Apollomics Inc , Granted Breakthrough Therapy Designation , Acute Myeloid , Breakthrough Therapy Designation , Drug Evaluation , Chief Executive , Investigational New Drug , Drug Registration Regulation ,